---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-145810"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:46:09.269613+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M

## Summary
- Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).
- Net loss $28.4M ($1.25/shr) vs $25.9M ($1.17/shr) a year ago.
- Cash, cash equivalents & marketable securities $137.1M at Mar 31, up from $89.8M.
- Reiterated FY2022 Jelmyto revenue guidance $70-80M and operating expenses $140-160M.
- Phase 3 ENVISION trial of UGN-102 enrollment expected to complete by end 2022; NDA submission projected 2024.

## SEC filing metadata
- accession: 0001193125-22-145810
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/0001193125-22-145810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/d261272d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-145810
- JSON: https://secwatch.observer/filing/0001193125-22-145810.json
- Plain text: https://secwatch.observer/filing/0001193125-22-145810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.